Regenesis
Cartilage Regeneration through Electrical Stimulations
Company Overview
Snapshot
Founded in February 2023, Regenesis operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing its innovative cartilage regeneration technology.
Business overview
Regenesis is a biomedical startup dedicated to revolutionizing the treatment of cartilage lesions. The company's core technology involves a unique biocompatible structure designed to enhance in situ cartilage regeneration through a minimally invasive procedure. This platform can be adapted for various medical conditions associated with cartilage damage, including hip and ankle lesions and Osteoarthritis (OA). Regenesis operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Biomaterials & Tissue Engineering.
Log in to access full profile ›Company Intelligence Q&A
- What is Regenesis' primary focus?
- Regenesis is focused on developing innovative solutions for cartilage regeneration, aiming to restore cartilage through minimally invasive procedures using a unique biocompatible structure.
- What medical conditions does Regenesis' platform address?
- The Regenesis platform is designed to address various medical conditions associated with cartilage damage, including hip and ankle lesions and Osteoarthritis (OA).
- When was Regenesis founded?
- Regenesis was founded in February 2023.
- What is the current stage of Regenesis' product development?
- Regenesis' product, the mESh Technology platform, is currently in the R&D stage.
- What is Regenesis' primary business model?
- Regenesis primarily operates with a B2B business model.